全文获取类型
收费全文 | 127085篇 |
免费 | 9873篇 |
国内免费 | 3617篇 |
专业分类
耳鼻咽喉 | 997篇 |
儿科学 | 2332篇 |
妇产科学 | 1815篇 |
基础医学 | 7179篇 |
口腔科学 | 2869篇 |
临床医学 | 15132篇 |
内科学 | 18983篇 |
皮肤病学 | 2310篇 |
神经病学 | 6439篇 |
特种医学 | 4059篇 |
外国民族医学 | 39篇 |
外科学 | 12635篇 |
综合类 | 18321篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5754篇 |
眼科学 | 2050篇 |
药学 | 10281篇 |
73篇 | |
中国医学 | 11099篇 |
肿瘤学 | 18183篇 |
出版年
2024年 | 308篇 |
2023年 | 2278篇 |
2022年 | 4168篇 |
2021年 | 5594篇 |
2020年 | 5311篇 |
2019年 | 4719篇 |
2018年 | 4501篇 |
2017年 | 4950篇 |
2016年 | 5251篇 |
2015年 | 5044篇 |
2014年 | 9089篇 |
2013年 | 11454篇 |
2012年 | 7437篇 |
2011年 | 7953篇 |
2010年 | 6569篇 |
2009年 | 6061篇 |
2008年 | 5904篇 |
2007年 | 6303篇 |
2006年 | 5638篇 |
2005年 | 4998篇 |
2004年 | 4045篇 |
2003年 | 3669篇 |
2002年 | 2991篇 |
2001年 | 2653篇 |
2000年 | 2210篇 |
1999年 | 1728篇 |
1998年 | 1425篇 |
1997年 | 1195篇 |
1996年 | 1002篇 |
1995年 | 902篇 |
1994年 | 713篇 |
1993年 | 542篇 |
1992年 | 488篇 |
1991年 | 444篇 |
1990年 | 380篇 |
1989年 | 334篇 |
1988年 | 323篇 |
1987年 | 278篇 |
1986年 | 218篇 |
1985年 | 257篇 |
1984年 | 230篇 |
1983年 | 173篇 |
1982年 | 168篇 |
1981年 | 168篇 |
1980年 | 138篇 |
1979年 | 125篇 |
1978年 | 65篇 |
1977年 | 42篇 |
1976年 | 50篇 |
1975年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
23.
《Journal of thoracic oncology》2020,15(4):618-627
IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. 相似文献
24.
25.
目的:观察非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)患者自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)术后应用重组人α-2b干扰素(α-2b IFN)进行早期干预治疗的临床疗效。方法:选取18例行ASCT的NHL患者为研究对象,移植前疾病评估均未达到完全缓解(complete remission,CR),试验组血象恢复后给予IFN 3 000 000 U次/隔日干预治疗,3个月后停用;对照组未行干扰素干预治疗,分析总体疗效及两组对比的生存情况。结果:随访中位时间为34(10~50)个月,患者中位生存时间为37(31~45)个月,3年总体无进展生存(progressive free survival,PFS)、总生存(overall survivial,OS)分别为54.7%、66.8%。ASCT后试验组1年内无疾病复发,2年内复发率为12.5%;对照组1年内复发率为20%,2年内复发率为30%。结论:NHL患者在ASCT后给予重组人α-2b IFN早期干预治疗,患者耐受性好,可能降低移植后早期复发率。 相似文献
26.
27.
28.
29.
《Journal of vascular and interventional radiology : JVIR》2020,31(12):1993-1997
PurposeTo examine the long-term clinical outcomes of patients with anti-centromere antibody (ACA)-positive critical limb-threatening ischemia (CLTI) who were treated with endovascular therapy (EVT).Materials and MethodsThis was a retrospective analysis using a database of 423 consecutive CLTI patients (543 limbs, Rutherford class 4–6) who underwent EVT between January 2011 and March 2013. The patients were divided into 2 groups: an ACA-positive group (10 limbs, 8 patients) and a control group (46 limbs, 43 patients). The control group was defined as female, non-dialysis, and those who were able to obtain a below-knee angiogram.ResultsNone of the 8 ACA-positive CLTI patients had previously been diagnosed as ACA positive. No significant difference was observed in the below-the-knee lesion distribution and severity between the ACA-positive group and the control group. The median observational period was 51 months. The survival rate was 54% in the ACA-positive group and 76% in the control group at 5 years after EVT (P = .732). The freedom from major amputation rate was 60% in the ACA-positive group and 91% in the control group at 5 years after EVT (P = .029). The technical EVT success rate in the ACA-positive group was 70% (7/10). Of the successful EVT cases, 71% (5/7) of patients achieved complete wound healing or rest pain relief; however, 60% (3/5) had a recurrence of wounds.ConclusionsIn a series of ACA-positive patients with CLTI, successful EVT had acceptable outcomes with respect to wound healing with short-term results. However, the major amputation rate for ACA-positive patients was high in long-term follow-up. 相似文献
30.